SPI Pharma Launches ValensTM to Unify Vaccine and Biologic Offerings

ValensTM is a new portfolio brand name from SPI Pharma that unites product offerings aimed at serving the vaccine, parenteral dosage form, and biologic medicine markets.

In order to support the rapidly expanding biologics drug excipients market, SPI Pharma's unique vaccine adjuvant products will first be grouped under the ValensTM brand. This brand will also be used to strategically brand new additions to the portfolio, with the goal of creating a comprehensive offering of parenteral excipients, vaccine ingredients, and materials.

For many years, SPI dominated the market for alum vaccine adjuvants. Now, to expand its offering, it has partnered with Q-Vant Biosciences to bring in sustainable saponin adjuvants. Additionally, SPI recently decided to work strategically with Inimmune Corp. to create and market cutting-edge adjuvant solutions. The business development team at SPI  is currently exploring several materials and pursuing potential partnerships to further enhance the portfolio.

Valens will set the high-value parenteral, biologic, and vaccine ingredients apart from the other pharmaceutical and consumer health products offered by SPI Pharma.

"The Latin term Valens means "strong, energetic, and healthy," and these qualities aptly characterise our ValensTM range of adjuvants and parenteral medicines. Our ValensTM portfolio, developed to improve life-saving vaccinations and medicines, embodies SPI Pharma's fundamental philosophy of making a difference. "We want to make these cutting-edge and complementary products available to everyone on the planet," stated John McInerney.